Latest News:

Gentronix Signs 3 Year Agreement with GlaxoSmith-Kline for GreenScreen and BlueScreen Assays....

New publication in the journal Mutation Research: Analysis of ECVAM recommended lists of genotoxic compounds with GreenScreen HC....

Gentronix launches a service offering for in vitro Comet assays.  Read more....

 

 

 

 

 

 

 

 

 

 

 

 



 

 

gentronix provides services and solutions that help companies reduce attrition rates and ensure safer products across a wide range of chemistry driven industries.

Our primary focus is on providing better hazard identification assays for genotoxicity through the use of our patented human cell GADD45a reporter assays GreenScreen® HC and BlueScreen HC.

In addition Gentronix provides out-sourced services for genotoxicity testing and a wide range of other ADME and predictive toxicity endpoints.


Reducing attrition rates due to toxicity concerns is critical to increasing the success of the drug discovery and development process. Identifying toxicity liability early allows precious resources to be directed towards compounds more likely to advance to candidate selection and on to clinical evaluation.

Currently 75 pharmaceutical and fine chemical companies in 15 countries are using GreenScreen HC data as part of their genotoxicity profiling strategy.

 

     Reagent Kits for
      Laboratory use

      Service Testing
       with Gentronix

    ADME Tox Profiling

 

  • GreenScreen HC & HC S9
  • BlueScreen HC & HC S9
  • For micro-plate readers
  • For flow cytometers
  • GreenScreen HC & HC S9
  • in vitro Comet assay
  • Test with the experts
  • 2 week turn-around
  • <10 mg of compound required
  • Cytotoxicity
  • Mitochondrial toxicity
  • Phospholipidosis
  • CYP Interactions
  • hERG, CaCo-2 and more…